PUBLISHER: TechNavio | PRODUCT CODE: 2125922
PUBLISHER: TechNavio | PRODUCT CODE: 2125922
Global Mycoplasma Testing Market 2026-2030
The global mycoplasma testing market is forecasted to grow by USD 1061.8 mn during 2025-2030, accelerating at a CAGR of 14.2% during the forecast period. The report on the global mycoplasma testing market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by expansion of biopharmaceutical and cell therapies, advancements in molecular testing technologies, rising incidence of respiratory infections.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
| Market Scope | |
|---|---|
| Base Year | 2025 |
| End Year | 2030 |
| Series Year | 2026-2030 |
| Growth Momentum | Accelerate |
| YOY 2026 | 12.4% |
| CAGR | 14.2% |
| Incremental Value | $1061.8 mn |
Technavio's global mycoplasma testing market is segmented as below:
By End-User
- Pharmaceutical and biotechnology companies
- Cell banks
- Academic research institutes
- CROs
- Others
By Product
- Consumables
- Systems
By Product Type
- Kits and reagents
- Services
- Instruments
Geography
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Asia
- Rest of World (ROW)
- Rest of World (ROW)
This study identifies the integration of automated detection systems as one of the prime reasons driving the global mycoplasma testing market growth during the next few years. Also, dominance of kits and reagents and expansion of cell and gene therapies will lead to sizable demand in the market.
The report on the global mycoplasma testing market covers the following areas:
- Global mycoplasma testing market sizing
- Global mycoplasma testing market forecast
- Global mycoplasma testing market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global mycoplasma testing market vendors that include Abcam plc, Bio Techne Corp., BioMerieux SA, Bionique Testing Laboratories, Charles River Laboratories, Creative Bioarray, Elabscience Biotechnology Inc., Eurofins Scientific SE, F. Hoffmann La Roche Ltd., InvivoGen Corp., Lonza Group Ltd., Merck KGaA, Minerva Biolabs GmbH, MP Biomedicals Inc., Norgen Biotek Corp., PromoCell GmbH, QIAGEN N.V., Sartorius AG, Shimadzu Corp., Sotera Health Co., SouthernBiotech, Thermo Fisher Scientific Inc., TransGen Biotech Co. Ltd., WuXi AppTec Co. Ltd.. Also, the global mycoplasma testing market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
- 1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by End-user
- Executive Summary - Chart on Market Segmentation by Product
- Executive Summary - Chart on Market Segmentation by Product Type
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
- 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- 2.2 Criticality of inputs and Factors of differentiation
- 2.3 Factors of disruption
- 2.4 Impact of drivers and challenges
3 Market Landscape
- 3.1 Market ecosystem
- 3.2 Market characteristics
- 3.3 Value chain analysis
4 Market Sizing
- 4.1 Market definition
- 4.2 Market segment analysis
- Market segments
- 4.3 Market size 2025
- 4.4 Market outlook: Forecast for 2025-2030
5 Historic Market Size
- 5.1 Global Mycoplasma Testing Market 2020 - 2024
- Historic Market Size - Data Table on Global Mycoplasma Testing Market 2020 - 2024 ($ million)
- 5.2 End-user segment analysis 2020 - 2024
- Historic Market Size - End-user Segment 2020 - 2024 ($ million)
- 5.3 Product segment analysis 2020 - 2024
- Historic Market Size - Product Segment 2020 - 2024 ($ million)
- 5.4 Product Type segment analysis 2020 - 2024
- Historic Market Size - Product Type Segment 2020 - 2024 ($ million)
- 5.5 Geography segment analysis 2020 - 2024
- Historic Market Size - Geography Segment 2020 - 2024 ($ million)
- 5.6 Country segment analysis 2020 - 2024
- Historic Market Size - Country Segment 2020 - 2024 ($ million)
6 Qualitative Analysis
- 6.1 Impact of AI on Global Mycoplasma Testing Market
- 6.2 Impact of geopolitical conflicts on Global Mycoplasma Testing Market
7 Five Forces Analysis
- 7.1 Five forces summary
- Five forces analysis - Comparison between 2025 and 2030
- 7.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2025 and 2030
- 7.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2025 and 2030
- 7.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2025 and 2030
- 7.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2025 and 2030
- 7.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2025 and 2030
- 7.7 Market condition
8 Market Segmentation by End-user
- 8.1 Market segments
- 8.2 Comparison by End-user
- 8.3 Pharmaceutical and biotechnology companies - Market size and forecast 2025-2030
- 8.4 Cell banks - Market size and forecast 2025-2030
- 8.5 Academic research institutes - Market size and forecast 2025-2030
- 8.6 CROs - Market size and forecast 2025-2030
- 8.7 Others - Market size and forecast 2025-2030
- 8.8 Market opportunity by End-user
- Market opportunity by End-user ($ million)
9 Market Segmentation by Product
- 9.1 Market segments
- 9.2 Comparison by Product
- 9.3 Consumables - Market size and forecast 2025-2030
- 9.4 Systems - Market size and forecast 2025-2030
- 9.5 Market opportunity by Product
- Market opportunity by Product ($ million)
10 Market Segmentation by Product Type
- 10.1 Market segments
- 10.2 Comparison by Product Type
- 10.3 Kits and reagents - Market size and forecast 2025-2030
- 10.4 Services - Market size and forecast 2025-2030
- 10.5 Instruments - Market size and forecast 2025-2030
- 10.6 Market opportunity by Product Type
- Market opportunity by Product Type ($ million)
11 Customer Landscape
- 11.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
12 Geographic Landscape
- 12.1 Geographic segmentation
- 12.2 Geographic comparison
- 12.3 North America - Market size and forecast 2025-2030
- 12.3.1 US - Market size and forecast 2025-2030
- 12.3.2 Canada - Market size and forecast 2025-2030
- 12.3.3 Mexico - Market size and forecast 2025-2030
- 12.4 Europe - Market size and forecast 2025-2030
- 12.4.1 Germany - Market size and forecast 2025-2030
- 12.4.2 UK - Market size and forecast 2025-2030
- 12.4.3 France - Market size and forecast 2025-2030
- 12.4.4 Italy - Market size and forecast 2025-2030
- 12.4.5 Spain - Market size and forecast 2025-2030
- 12.4.6 The Netherlands - Market size and forecast 2025-2030
- 12.5 Asia - Market size and forecast 2025-2030
- 12.5.1 China - Market size and forecast 2025-2030
- 12.5.2 India - Market size and forecast 2025-2030
- 12.5.3 Japan - Market size and forecast 2025-2030
- 12.5.4 South Korea - Market size and forecast 2025-2030
- 12.5.5 Indonesia - Market size and forecast 2025-2030
- 12.5.6 Thailand - Market size and forecast 2025-2030
- 12.6 Rest of World (ROW) - Market size and forecast 2025-2030
- 12.6.1 Brazil - Market size and forecast 2025-2030
- 12.6.2 Saudi Arabia - Market size and forecast 2025-2030
- 12.6.3 UAE - Market size and forecast 2025-2030
- 12.6.4 Turkey - Market size and forecast 2025-2030
- 12.6.5 Argentina - Market size and forecast 2025-2030
- 12.6.6 Colombia - Market size and forecast 2025-2030
- 12.6.7 South Africa - Market size and forecast 2025-2030
- 12.6.8 Israel - Market size and forecast 2025-2030
- 12.7 Market opportunity by geography
- Market opportunity by geography ($ million)
- Data Tables on Market opportunity by geography ($ million)
13 Drivers, Challenges, and Opportunity
- 13.1 Market drivers
- Expansion of biopharmaceutical and cell therapies
- Advancements in molecular testing technologies
- Rising incidence of respiratory infections
- 13.2 Market challenges
- High costs of advanced testing equipment
- Regulatory validation and compliance lags
- High market concentration barriers
- 13.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2025 and 2030
- 13.4 Market opportunities
- Integration of automated detection systems
- Dominance of kits and reagents
- Expansion of cell and gene therapies
14 Competitive Landscape
- 14.1 Overview
- 14.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
- 14.3 Landscape disruption
- Overview on factors of disruption
- 14.4 Industry risks
- Impact of key risks on business
15 Competitive Analysis
- 15.1 Companies profiled
- Companies covered
- 15.2 Company ranking index
- Company ranking index
- 15.3 Market positioning of companies
- Matrix on companies position and classification
- 15.4 Abcam plc
- Abcam plc - Overview
- Abcam plc - Product / Service
- Abcam plc - Key offerings
- SWOT
- 15.5 Bio Techne Corp.
- Bio Techne Corp. - Overview
- Bio Techne Corp. - Business segments
- Bio Techne Corp. - Key news
- Bio Techne Corp. - Key offerings
- Bio Techne Corp. - Segment focus
- SWOT
- 15.6 BioMerieux SA
- BioMerieux SA - Overview
- BioMerieux SA - Business segments
- BioMerieux SA - Key offerings
- BioMerieux SA - Segment focus
- SWOT
- 15.7 Charles River Laboratories
- Charles River Laboratories - Overview
- Charles River Laboratories - Business segments
- Charles River Laboratories - Key offerings
- Charles River Laboratories - Segment focus
- SWOT
- 15.8 Elabscience Biotechnology Inc.
- Elabscience Biotechnology Inc. - Overview
- Elabscience Biotechnology Inc. - Product / Service
- Elabscience Biotechnology Inc. - Key offerings
- SWOT
- 15.9 Eurofins Scientific SE
- Eurofins Scientific SE - Overview
- Eurofins Scientific SE - Business segments
- Eurofins Scientific SE - Key offerings
- Eurofins Scientific SE - Segment focus
- SWOT
- 15.10 F. Hoffmann La Roche Ltd.
- F. Hoffmann La Roche Ltd. - Overview
- F. Hoffmann La Roche Ltd. - Business segments
- F. Hoffmann La Roche Ltd. - Key news
- F. Hoffmann La Roche Ltd. - Key offerings
- F. Hoffmann La Roche Ltd. - Segment focus
- SWOT
- 15.11 Lonza Group Ltd.
- Lonza Group Ltd. - Overview
- Lonza Group Ltd. - Business segments
- Lonza Group Ltd. - Key news
- Lonza Group Ltd. - Key offerings
- Lonza Group Ltd. - Segment focus
- SWOT
- 15.12 Merck KGaA
- Merck KGaA - Overview
- Merck KGaA - Business segments
- Merck KGaA - Key news
- Merck KGaA - Key offerings
- Merck KGaA - Segment focus
- SWOT
- 15.13 QIAGEN N.V.
- QIAGEN N.V. - Overview
- QIAGEN N.V. - Product / Service
- QIAGEN N.V. - Key offerings
- SWOT
- 15.14 Sartorius AG
- Sartorius AG - Overview
- Sartorius AG - Business segments
- Sartorius AG - Key offerings
- Sartorius AG - Segment focus
- SWOT
- 15.15 Shimadzu Corp.
- Shimadzu Corp. - Overview
- Shimadzu Corp. - Business segments
- Shimadzu Corp. - Key offerings
- Shimadzu Corp. - Segment focus
- SWOT
- 15.16 Sotera Health Co.
- Sotera Health Co. - Overview
- Sotera Health Co. - Business segments
- Sotera Health Co. - Key offerings
- Sotera Health Co. - Segment focus
- SWOT
- 15.17 Thermo Fisher Scientific Inc.
- Thermo Fisher Scientific Inc. - Overview
- Thermo Fisher Scientific Inc. - Business segments
- Thermo Fisher Scientific Inc. - Key news
- Thermo Fisher Scientific Inc. - Key offerings
- Thermo Fisher Scientific Inc. - Segment focus
- SWOT
- 15.18 WuXi AppTec Co. Ltd.
- WuXi AppTec Co. Ltd. - Overview
- WuXi AppTec Co. Ltd. - Business segments
- WuXi AppTec Co. Ltd. - Key offerings
- WuXi AppTec Co. Ltd. - Segment focus
- SWOT
16 Appendix
- 16.1 Scope of the report
- Market definition
- Objectives
- Notes and caveats
- 16.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
- 16.3 Currency conversion rates for US$
- Currency conversion rates for US$
- 16.4 Research methodology
- Research methodology
- 16.5 Data procurement
- Information sources
- 16.6 Data validation
- Data validation
- 16.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
- 16.8 Data synthesis
- Data synthesis
- 16.9 360 degree market analysis
- 360 degree market analysis
- 16.10 List of abbreviations
- List of abbreviations
